Esbriet is the brand name for the oral antifibrotic medication pirfenidone. It is supplied as a pill available in 200 mg and 400 mg strengths. In Hong Kong, Esbriet is a prescription-only product approved by the Department of Health for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive scarring disease of the lungs. The medication is classified under the broader therapeutic area of asthma & breathing disorders, although its specific indication is IPF.
Pirfenidone exerts its effect through several antifibrotic and anti-inflammatory mechanisms:
These actions collectively slow the progression of scarring, improve lung function, and may extend survival in patients with IPF. Onset of effect usually occurs over weeks, with the full therapeutic benefit becoming apparent after several months of continuous therapy.
There are no approved uses for asthma, chronic obstructive pulmonary disease, or other breathing disorders.
Patients should provide a full medication list, including over-the-counter products and herbal supplements, to their prescriber.
Standard titration (per prescribing information):
Week 1: 200 mg three times daily (taken with food).
Weeks 2-4: Increase by 200 mg each week until reaching the target maintenance dose of 600 mg three times daily (total 1800 mg per day).
The target dose can be assembled using a combination of 200 mg and 400 mg tablets as directed by the prescriber.
Administration tips:
Swallow tablets whole; do not crush or chew.
Consistency with food helps reduce nausea.
Missed dose:
If a dose is forgotten and the next scheduled dose is more than 12 hours away, take the missed dose. Otherwise, skip it and resume the regular schedule. Do not double-dose.
Overdose:
Symptoms may include severe nausea, vomiting, abdominal pain, and elevated liver enzymes. Seek emergency medical care; supportive treatment is the mainstay.
Discontinuation:
Abrupt cessation is permissible, but clinicians may advise a gradual taper if the patient has tolerated the medication for a prolonged period to reduce the risk of IPF flare-ups.
All dosing decisions must be individualized by a qualified healthcare provider.
This article provides educational information about Esbriet and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Esbriet is a brand-named product that contains the same active ingredient, pirfenidone, as generic versions. The clinical effect is identical; differences may lie in packaging, pricing, and manufacturer reputation.
The medication should be taken with meals to reduce gastrointestinal upset such as nausea and dyspepsia.
Moderate alcohol intake is not strictly prohibited, but excessive drinking can aggravate liver toxicity, so patients with liver concerns should limit alcohol.
Pirfenidone does not impair cognition or motor function; however, severe fatigue may affect alertness, so patients should assess how they feel before driving.
If the next scheduled dose is more than 12 hours away, take the missed dose; otherwise, skip it and continue with the regular dosing schedule. Do not double the dose.
Clinical benefits are typically observed after several months of continuous therapy; lung function tests are used to monitor progress rather than symptom perception alone.
There are no specific dietary restrictions, but patients should maintain a balanced diet and stay well-hydrated to help mitigate gastrointestinal side effects.
Smoking induces the CYP1A2 enzyme, which can lower pirfenidone levels and potentially reduce its antifibrotic effect. Quitting smoking is strongly advised.
Keep the tablets at room temperature, protected from moisture and direct sunlight, and out of reach of children.
Coverage varies by individual insurance plans and the public scheme’s formulary; patients should check with the Hospital Authority or their private insurer for specific reimbursement details.
